Franklin Genomic Advancements ETF Rating $28.55 -1.41 (-4.71%) (As of 11/15/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatings Franklin Genomic Advancements ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HELX Aggregate RatingModerate Buy2.73Holdings in HELX have an aggregate rating of Moderate Buy based on 668 analyst ratings issued in the past year covering 46 companies (89.9% of the portfolio).HELX Aggregate Price Target$28.55High Prediction$28.55Average Prediction$28.55Low Prediction$28.55Holdings in HELX have an aggregate price target of $28.55 and a range of $28.55 to $28.55 covering 46 companies (89.9% of the portfolio).HELX Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy8 Buy rating(s)Moderate Buy31 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Franklin Genomic Advancements ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 46 HELX Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.91%MEDPMedpace$310.63-7.2%4.7476 of 5 stars2.45$380.00 22.3%11High Trading Volume5.79%VRTXVertex Pharmaceuticals$465.70-3.8%3.546 of 5 stars2.53$499.12 7.2%30Analyst UpgradeNews CoveragePositive NewsHigh Trading Volume5.27%DHRDanaher$230.50-3.7%4.9494 of 5 stars2.74$287.16 24.6%19Analyst RevisionNews CoveragePositive News5.00%REGNRegeneron Pharmaceuticals$756.81-3.3%4.8092 of 5 stars2.78$1,099.55 45.3%23Analyst UpgradeNews Coverage4.97%LLYEli Lilly and Company$746.20-4.9%4.9843 of 5 stars2.81$1,007.94 35.1%21Analyst ForecastNews CoveragePositive News4.96%TMOThermo Fisher Scientific$513.08-3.7%4.9932 of 5 stars2.86$649.33 26.6%22Insider SellingBuyback AnnouncementAnalyst RevisionNews CoveragePositive NewsHigh Trading Volume4.25%KRYSKrystal Biotech$170.74-3.7%4.7832 of 5 stars3.00$197.00 15.4%93.80%NTRANatera$146.06-3.3%2.8484 of 5 stars3.00$137.65 -5.8%17Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews Coverage2.68%AZNAstraZeneca$63.23-2.8%4.166 of 5 stars3.00$89.75 41.9%11Earnings ReportShort Interest ↑Gap Down2.27%CTVACorteva$55.21-3.8%4.7184 of 5 stars2.67$63.68 15.3%21Options VolumeNews Coverage2.11%INSMInsmed$66.29-7.0%4.4008 of 5 stars3.00$83.07 25.3%16Positive NewsHigh Trading Volume2.08%AAgilent Technologies$127.07-2.4%4.7586 of 5 stars2.50$144.36 13.6%14Short Interest ↑Positive News2.05%IONSIonis Pharmaceuticals$34.34-7.8%4.2688 of 5 stars2.68$60.65 76.6%19Analyst DowngradeInsider SellingShort Interest ↑News Coverage2.01%BRKRBruker$51.30-5.9%4.9952 of 5 stars2.55$79.36 54.7%11Short Interest ↓1.99%ALNYAlnylam Pharmaceuticals$235.56-8.7%4.8183 of 5 stars2.71$294.50 25.0%24Analyst DowngradeShort Interest ↓1.98%CDNSCadence Design Systems$289.71-4.4%4.8605 of 5 stars2.77$326.00 12.5%13Short Interest ↑News CoveragePositive News1.95%CRLCharles River Laboratories International$187.74-4.7%4.773 of 5 stars2.00$217.54 15.9%15Insider SellingShort Interest ↓1.86%UTHRUnited Therapeutics$363.25-6.0%4.5216 of 5 stars2.73$370.86 2.1%15Insider SellingNews CoveragePositive News1.85%BNTXBioNTech$99.72-3.7%3.521 of 5 stars2.79$137.54 37.9%14Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading Volume1.85%QGENQiagen$41.27-1.9%4.2961 of 5 stars2.60$50.88 23.3%10Analyst Revision1.73%EXASExact Sciences$49.33-3.1%4.862 of 5 stars2.95$74.47 51.0%19Insider BuyingShort Interest ↓1.66%ICLRICON Public$189.64-5.2%4.7116 of 5 stars2.86$304.27 60.4%14Short Interest ↓News Coverage1.57%RCKTRocket Pharmaceuticals$13.98-5.7%4.1699 of 5 stars2.90$51.75 270.2%10Analyst Revision1.56%SRPTSarepta Therapeutics$104.54-4.2%4.9282 of 5 stars3.00$181.33 73.5%22Analyst Upgrade1.48%RVTYRevvity$109.52-5.6%3.9599 of 5 stars2.65$132.07 20.6%17Positive News1.46%RAREUltragenyx Pharmaceutical$44.75-6.1%4.6361 of 5 stars2.92$86.69 93.7%13Analyst Forecast1.22%TWSTTwist Bioscience$36.89-5.3%3.4863 of 5 stars2.67$51.22 38.9%9Upcoming EarningsInsider SellingNews CoverageHigh Trading Volume1.13%IQVIQVIA$192.68-5.1%4.9877 of 5 stars2.84$259.13 34.5%19News CoveragePositive NewsHigh Trading Volume1.11%VYGRVoyager Therapeutics$5.64-9.3%4.6724 of 5 stars3.00$17.00 201.4%9Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.97%LHLaboratory Co. of America$235.21-1.2%4.7942 of 5 stars2.80$255.92 8.8%15Insider SellingNews CoveragePositive NewsHigh Trading Volume0.92%BBIOBridgeBio Pharma$23.72-1.6%4.6086 of 5 stars2.87$47.57 100.6%15Analyst ForecastAnalyst RevisionNews Coverage0.91%TECHBio-Techne$67.57-6.9%4.7335 of 5 stars2.67$81.78 21.0%9Analyst UpgradeHigh Trading Volume0.88%LGNDLigand Pharmaceuticals$111.71-3.2%4.9884 of 5 stars3.00$144.83 29.7%6Analyst Forecast0.86%BEAMBeam Therapeutics$24.05-8.6%3.0461 of 5 stars2.75$44.91 86.7%12Short Interest ↑0.86%AZTAAzenta$41.51-2.6%3.3699 of 5 stars2.40$63.60 53.2%5Earnings ReportAnalyst ForecastShort Interest ↓News Coverage0.84%NBIXNeurocrine Biosciences$117.44-4.4%4.9651 of 5 stars2.83$163.91 39.6%24Positive News0.83%NTLAIntellia Therapeutics$13.97-7.6%4.5381 of 5 stars2.75$55.36 296.3%16Gap Up0.80%CDMOAvid Bioservices$12.14+1.8%3.5113 of 5 stars2.40$13.63 12.2%5Positive News0.79%MRNAModerna$36.85-7.3%4.5645 of 5 stars2.05$90.22 144.8%21Analyst ForecastOptions VolumeGap DownHigh Trading Volume0.65%CRSPCRISPR Therapeutics$47.25+0.9%1.8645 of 5 stars2.37$74.94 58.6%19Insider SellingShort Interest ↑News Coverage0.57%RXRXRecursion Pharmaceuticals$6.18-10.7%2.1275 of 5 stars2.40$9.25 49.8%5Insider SellingHigh Trading Volume0.54%RGENRepligen$124.73-12.4%4.6434 of 5 stars2.73$190.25 52.5%11Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoverageHigh Trading Volume0.53%BIOBio-Rad Laboratories$320.31-8.5%4.7381 of 5 stars2.60$391.80 22.3%5Short Interest ↓News CoveragePositive News0.50%AVTRAvantor$20.74-1.9%4.9822 of 5 stars2.80$27.57 32.9%15Options VolumeAnalyst RevisionPositive News0.44%FDMT4D Molecular Therapeutics$8.83+10.1%3.3479 of 5 stars2.89$47.00 432.3%9Analyst ForecastShort Interest ↓Analyst RevisionNews Coverage0.41%NGNENeurogene$34.52-12.0%2.9859 of 5 stars3.11$63.33 83.5%9Analyst ForecastNews Coverage This page (BATS:HELX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
